Boston Scientific is taking unused Infinion CX leads for its spinal cord stimulator systems off the shelf, and the Food and Drug Administration has classified the removal as a Class I action, its most serious recall category.
The single most important fact for patients is one the classification label does not convey. This recall covers unused inventory only. It does not ask anyone to have an implanted lead taken out, and the company's notice to customers states plainly that already-implanted devices are not affected. For leads already in use, the company recommends continuing routine follow-up.
That distinction is easy to lose. Boston Scientific has reported 1,081 serious injuries and no deaths in connection with the underlying problem, a number that sounds like a mass patient recall and is not one. Those reports accumulated over years of implanted use. The action now being taken is a stock pull of about 1,079 unused leads, most of them outside the United States.
The Injury Number and the Recall Are Measuring Different Things
The defect is mechanical. According to the FDA's recall record, the lead body can be exposed to stress where it is anchored, which may produce high impedance readings or a fracture in the lead. When that happens, stimulation can become inadequate, and correcting it may require another procedure, including removing and replacing the lead. The agency listed the cause as device design.
Boston Scientific's field safety notice reported that the leads fractured about one percent of the time between September 2014 and April of this year. That is the rate behind the injury total. A one percent failure rate across more than a decade of implants in a widely used device produces a large absolute number without meaning that a given patient is likely to be affected.
The recall record also contains a detail that reframes the action. The company describes the removal of unused leads as part of a planned transition to the next-generation lead, the Infinion Pro, which was designed with a changed lead body configuration. A product changeover and a safety removal are happening at the same time, and readers deserve to know both appear in the notice.
Small American Footprint, Wide International One
The FDA record lists United States distribution for this recall in a single state, New York. The remaining affected inventory sits in Canada, much of Western Europe, Brazil, Colombia, Argentina, Israel, and the United Arab Emirates, among others.
For a Class I designation, that is an unusually narrow domestic footprint, and it reflects what is actually being removed: leftover unimplanted stock, not devices in patients. Americans living with an Infinion CX lead are not counted in that figure of 1,079.
The timeline is also worth stating precisely, because some secondary summaries have muddled it. Boston Scientific initiated the action on June 17. The FDA posted the Class I classification on August 5. The recall remains open, meaning not all product has been removed.
Signs a Stimulator Patient Should Actually Watch For
Spinal cord stimulators are implanted for chronic pain of the back and limbs, often after other options have failed. People who rely on them tend to have long, difficult treatment histories, and the prospect of a device problem carries real weight.
The symptom that matters is a change in how the device works. Stimulation that weakens, becomes inconsistent, shifts location, stops covering the area it used to cover, or produces uncomfortable sensations can indicate a lead problem. So can a device that reports abnormal impedance during a check, which is a standard part of follow-up after implantation. None of these are emergencies, and none of them prove a fracture, since leads can also shift position or a battery can age.
The reasonable response is a call to the implanting physician or pain specialist for a device check, not an emergency room visit. Anyone whose device is working normally has no reason to seek unscheduled evaluation based on this recall. Patients should not stop using the device or change pain medication on their own.
It is also worth knowing which lead is implanted. Many patients do not, and the information sits in the operative report and on the device registration card issued at implantation. Asking the pain clinic to confirm the model at the next scheduled visit is a low-effort step that makes any future notice easier to act on. Patients who have moved, changed insurers, or lost touch with the original implanting practice are the ones most likely to fall outside a manufacturer notification, since those letters travel through the implanting facility rather than directly to patients.
Cost and access questions are fair to raise early. A revision procedure carries facility and physician charges, and coverage varies by plan and by whether the procedure is considered medically necessary. Patients facing a possible revision can ask their clinic about prior authorization, and about whether the manufacturer offers any support for device replacement, before scheduling.
The Broader Device Picture
This is the latest in a run of Class I actions involving Boston Scientific products. The company's Accolade pacemaker family drew a Class I correction in May over a battery impedance issue addressed by a software update, and its Endotak Reliance defibrillation leads were the subject of a Class I recall last year. MedicalDaily reported separately on an early alert involving the company's carotid catheters after reports of tips separating during use.
These are distinct products with distinct failure modes, and grouping them into a single narrative about one manufacturer would misstate the evidence. Class I classifications are also more common than the alarming label suggests, since the FDA applies it based on potential for serious harm rather than on confirmed outcomes.
What remains unresolved is whether the design issue is fully addressed in the replacement lead, and how many of the reported injuries required revision surgery. Neither the company nor the agency has published that breakdown. The recall status stays open until the removal is complete.
Key Questions Answered
Do I need my implanted lead removed? No. The recall covers unused leads in inventory. Boston Scientific's notice states the action does not affect devices that have already been implanted, and recommends that routine follow-up continue.
What does the 1,081 figure represent? It is the number of serious injuries reported in connection with the lead fracture and impedance issue as of May 27, accumulated across years of implanted use. No deaths have been reported.
How often do these leads fail? The company reported a fracture rate of about one percent between September 2014 and April 2026.
What symptoms suggest a problem? Stimulation that weakens, becomes inconsistent, changes location, or stops covering the treated area, or an abnormal impedance reading during a device check. Contact the implanting physician rather than an emergency department.
Why is it Class I if implanted devices are fine? The FDA assigns Class I based on the potential for serious harm from the defect, including the possibility of additional surgery. The classification describes the defect, not the removal scope.
How many leads are being removed and where? About 1,079 unused leads. United States distribution is listed in New York only, with the rest across Canada, Europe, South America, and the Middle East.
Is this connected to the new Infinion Pro lead? The recall record describes the removal as part of a planned transition to the next-generation lead. The safety issue and the product changeover appear in the same notice.
